





State of the Art in the Prevention and Control of Dengue in the Americas • 28 - 29 May, 2014 • Washington DC, USA





Meeting on the State of the Art for the prevention and control of dengue in the Americas

Neglected, Tropical and Vector Borne Diseases (CHA/VT)

May 28-29, 2014 Washington DC, USA









Background

Dengue is the vector borne viral infection most widely and further spread in the world, representing a severe public health problem. The infection is caused by the dengue virus, of which four serotypes (Denv1, Denv2, Denv3 and Denv4) are known, and the main vector in the Americas is the Aedes aegypti. This disease has no boundaries or limits, affecting populations of all ages and socio-economic levels. It is estimated that 2.5 billion people live in endemic countries, with 50 to 100 million cases per year approximately. The Americas are not an exception, the dengue incidence has increased 30 times in the last fifty years, and between 2008 and 2012 more than 1.2 million cases were notified annually, including 28,233 severe cases and 1,000 deaths. Furthermore, 2013 had the highest burden of disease ever registered, with the largest epidemic in the history of the Americas, with a total of 2.3 million cases, 37,692 severe cases and 1,280 deaths. This disease has a high social and economic impact, affecting not just the patient, but also his family and the community as a whole. The estimated economic cost of the disease supersedes 1,800 million dollars per year.

PAHO/WHO, through the Dengue Regional Program, supports member states in the implementation of the Integrated Management Strategy for the Prevention and Control of dengue (IMS -Dengue). This strategy was supported by the countries of the Americas, through the Resolution of Governing Bodies CD44.R9 in 2003; and since then, 22 countries of the Americas have developed a national IMS-Dengue. In addition, 20 countries have also completed an assessment of this strategy, with support of experts from the International Technical Group on dengue (ITG-Dengue), following the recommendations of Resolution CSP27.R15, adopted in 2007 by the 27th Pan American Health Organization Sanitary Conference.

Among the current efforts of the Regional Dengue Program are the following: 1) Strengthen epidemiological surveillance of dengue, through the development of a generic model of integrated epidemiological surveillance systems, 2) through RELDA, strengthen the capacity of the laboratory networks in the management of effective practices in the diagnosis of dengue, 3) Vector monitoring and control through the strengthen of Entomology, integrated vector management, and monitoring of insecticide resistance, 4) clinical management of patients, through the adaptation for the Americas of the WHO clinical guidelines published in 2009. A second edition of this adaptation is currently being carried out, and 5) social communication, which uses communication methodologies to impact behavior of the population facing the dengue problem.

This meeting will include presentations and discussions, with the highest of academic rigor, the most up to date topics in the management and prevention of dengue, as well as the initiatives and actions currently evolving in the Americas.







State of the Art in the Prevention and Control of Dengue in the Americas • 28 - 29 May, 2014 • Washington DC, USA

Objectives:

- 1. Review the currently available knowledge and experience for surveillance, detection, diagnosis, management, treatment and prevention of dengue.
- 2. Derive conclusions and recommendations, based on above, that serve the Dengue Regional Program to modify and update its strategies and technical cooperation plans, as well as its role in the fight to prevent and control this disease in the Americas.
- 3. Learn from the experiences of some countries in the Americas, who have been focusing on generating more information to be able to better approach this disease.
- 4. Learn the (preliminary) results of a systematic review about the research areas and gaps in dengue.







Wednesday, May 28, Room B

Coordinator: Dr. Tamara Mancero, PAHO/WHO

Time	Dr. Tamara Mancero, PAHO/WHO Content	Participants	
0.20 0.00	0	Dr. Francisco Becerra	
8:30 – 9:00 am	Opening Remarks	Assistant Director, PAHO/WHO	
		Dr. Luis G. Castellanos	
9:00 - 9:20 am	Participant introductions, review of agenda and	Unit Chief, Neglected, Tropical and Vector	
	introduction	Borne Diseases, PAHO/WHO	
Session 1			
Facilitator: Dr. Luis Gerardo Castellanos, PAHO/WHO			
	Dengue situation in the world; the WHO	Dr. Raman Velayudhan	
9:20 - 9:40 am	perspective	Coordinator, Vector Ecology and Management	
		HTM/NTD, WHO Geneva	
9:40 – 10:00 am	Dengue situation in the Americas; the PAHO	Dr. José Luis San Martín	
10.00	perspective	Regional Dengue Advisor PAHO/WHO	
10:00 – 10:15 am	Plenary Session 1		
10:15 –10:30 am	Coffee	break	
Session 2			
	Facilitator: Dr. José Luis San Martín,	PAHO/WHO	
10:30 – 11:45 am	Round table: Implementation of the IMS-Dengue		
	in Latin America and the Caribbean.	CIT D	
	(15 minutes per presentation)	GT-Dengue*:	
	• Communication	Dr. Linda Lloyd	
	Laboratory surveillance	Dr. Elizabeth Hunsperger Dr. Ernesto Pleités	
	• Care for patients	Dr. Haroldo Bezerra	
	Integrated vector management	Dr. Ángel Álvarez	
11 45 10 20	Epidemiology	Di. Tinger Tirvarez	
11:45 -12:30 pm	Plenary Session 2		
12:30 – 2:00 pm	Lun	ch	
	Session 3		
2.00 2.40 mm	Facilitator: Dr. Franklin Hernández, Experience of Brazil and Mexico in the IMS—	Dr. Giovanini Coelho (Brazil)	
2:00 - 2:40 pm	Dengue (20 min per presentation)	Dr. Cuauhtémoc Mancha (Mexico)	
2:40 – 3:25 pm	Plenary Session 3	Di. Cuauntemoc Mancha (Mexico)	
	-		
3:25 – 3:40 pm	Coffee break		
	Session 4 Facilitator: Dr. Siripen Kalayanarooj, WHO colla	phoreting center Theiland	
3:40 – 4: 40 pm	Round table: The work of the PAHO/WHO		
5.40 4. 40 pm	collaborating centers in Latin America and the		
	Caribbean (15 min per presentation)	Collaborators:	
	• IPK (Cuba)	Dr. Maria G. Guzmán	
	• CDC (USA)	Dr. Harold Margolis	
	Evandro Chagas Institute (Brazil)	Dr. Pedro Vasconcelos	
	National Institute of Human Viral	Dr. Delia Enria	
	Diseases (Argentina)		
4:40 – 5:25 pm	Plenary Session 4		
5:25 – 5:40 pm	Closing Remarks	Dr. José Luis San Martín, PAHO/WHO	
	0		







Thursday, May 29, Room B

Coordinator: Dr. Aída Soto, PAHO/WHO

Time	Content	Participants	
Session 5			
Facilitator: Dr. Angel Alvarez, PAHO/WHO			
8:30 – 8:50 am	Economic impact of dengue and dengue hemorrhagic fever in Zulia, Venezuela	Dr. Germán Añez, Researcher	
8:50 – 9:30 am	Studies on the socioeconomic burden of dengue. (20 min per presentation). • Andes University, Bogota-Colombia • National Autonomous University of Mexico	Speakers: Raul Castro, Associated Professor Dr. Adriana Zubieta Zavala	
9:30 – 9:45 am	Financial resources for the prevention and control of dengue in the Americas - PAHO/WHO	Dr. Luis G. Castellanos PAHO/WHO	
9:45 – 10:30 am	Plenary Session 5		
10:30 – 10:50 am	Group picture (Room A)		
10:50 – 11:05 am	Coffee break		
Session 6			
Facilitator: Dr. Zaida Yadón, PAHO/WHO			
11:05am–12:15 pm 12:15 – 1:00 pm	Research on dengue: Dengue Research and Capacity Strengthening: An Overview of Activities at the Special Program for Research and Training in Tropical Diseases (TDR), with Focus on the Americas (20 min) Preliminary results of a systematic review on dengue during the last 5 years (20min) The role of USG technologies in the advancement of biomedical science (15 min) NIAID resources for dengue research (15min) Plenary Session 6	Speakers: Dr. Piero Luigi Olliaro - TDR/WHO Dr. Gamaliel Gutiérrez - PAHO/WHO Dr. Margarita Ossorio - NIH Dr. Cristina Cassetti - NIH	
1:00 – 2:30 pm	Lunch		
Session 7 Facilitator: Dr. José Luis San Martín, PAHO/WHO			
2:30 – 3:30 pm	Round table: Update and development of new technologies in dengue control and prevention (20 min per presentation) • Vaccines and drugs • Other technologies in the control of Ae. Aegypti • Modeling in dengue control	Dr. Andrea Vicari – PAHO / WHO Dr. Haroldo Bezerra - PAHO/WHO Dr. Andrea Vicari - PAHO / WHO	
3:30 – 4:25 pm	Plenary Session 7		
4:25 – 4:40 pm	Coffee break		
4:40 – 5:10 pm	Closing Remarks Conclusions and recommendations	Dr. Luis Gerardo Castellanos PAHO/WHO	